Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

ROCKET AF Investigators, Manesh R Patel, Kenneth W Mahaffey, Jyotsna Garg, Guohua Pan, Daniel E Singer, Werner Hacke, Günter Breithardt, Jonathan L Halperin, Graeme J Hankey, Jonathan P Piccini, Richard C Becker, Christopher C Nessel, John F Paolini, Scott D Berkowitz, Keith A A Fox, Robert M Califf

Research output: Contribution to journalArticlepeer-review

Abstract

The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin.
Original languageEnglish
Pages (from-to)883-891
Number of pages9
JournalNew England Journal of Medicine
Volume365
Issue number10
DOIs
Publication statusPublished - 2011

Fingerprint

Dive into the research topics of 'Rivaroxaban versus warfarin in nonvalvular atrial fibrillation'. Together they form a unique fingerprint.

Cite this